{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-024071","form_type":"8-K","ticker":"SPRB","cik":"0001683553","company_name":"SPRUCE BIOSCIENCES, INC.","filed_at":"2023-05-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.029608+00:00","generated_at":"2026-06-14T14:41:08.315301+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Spruce Biosciences director Dina Chaya resigns; Percival Barretto-Ko appointed to board","bullets":["Dina Chaya, Ph.D., C.F.A. resigns from board and committees effective May 25, 2023; not due to any dispute.","Daniel Spiegelman appointed to Nominating Committee; Kirk Ways, M.D., Ph.D. named Chair of Nominating Committee.","Percival Barretto-Ko appointed as Class II director (term to 2025 annual meeting) and to Audit Committee.","Barretto-Ko receives option to purchase 60,000 shares vesting over 3 years, plus annual retainers of $40,000 (director) and $7,500 (audit)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-024071","json":"https://secwatch.observer/filing/0000950170-23-024071.json","markdown":"https://secwatch.observer/filing/0000950170-23-024071.md","text":"https://secwatch.observer/filing/0000950170-23-024071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1683553/000095017023024071/0000950170-23-024071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1683553/000095017023024071/sprb-20230522.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T14:41:08.315301+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"480998ae4b","claim":"Dina Chaya resigned as Director at SPRUCE BIOSCIENCES, INC..","evidence_excerpt":"On May 22, 2023, Dina Chaya, Ph.D., C.F.A., notified the board of directors (the “Board”) of Spruce Biosciences, Inc. (the “Company”) of her resignation as a director of the Company and as a member of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”) and the Audit Committee of the Board (the “Audit Committee”), effective as of May 25, 2023 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1683553/000095017023024071/0000950170-23-024071-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e1f5e1e56c","claim":"Percival Barretto-Ko was appointed as Class II Director at SPRUCE BIOSCIENCES, INC..","evidence_excerpt":"On May 23, 2023, the Board appointed Percival Barretto-Ko to the Board, to fill the vacancy resulting from Dr. Chaya's resignation, contingent upon Dr. Chaya's resignation and effective as of the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1683553/000095017023024071/0000950170-23-024071-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}